Tag Archives: Fluidigm

January 2021—Fluidigm received emergency use authorization from the FDA for the Advanta Dx SARS-CoV-2 RT-PCR assay, an extraction-free, saliva-based test to detect nucleic acid from the SARS‑CoV‑2 virus. The test runs on the Fluidigm Biomark HD microfluidics platform, which can generate as many as 6,000 test results in one day.

March 2019—Fluidigm introduced its Maxpar Human Immune Monitoring Panel Kit for comprehensive immune cell profiling in cancer and immune-mediated diseases. The immune monitoring kit contains 29 metal-labeled antibodies and reagents designed for deep immune profiling of human peripheral blood mononuclear cells in one tube.